Lymphoma Research Foundation publishes White Paper to outline key issues discussed during Oral Therapies workshop
In September 2015, The Lymphoma Research Foundation (LRF) convened scientists, clinicians, advocates, pharmaceutical industry representatives, and federal lawmakers and regulators for a workshop on Oral Therapies in Lymphoma. Lymphoma and chronic lymphocytic leukemia (CLL) are a complex group of malignancies traditionally managed by cytotoxic chemotherapy, immunotherapy, radiation treatment, and, in some cases, by high dose chemotherapy and stem cell transplantation. Recognizing that cancer care has entered a new era in which targeted oral anti-lymphoma agents are quickly changing treatment paradigms and providing a unique opportunity to improve patient outcomes and survival, LRF hosted the meeting to identify the specific challenges facing the scientific and patient communities related to the development, optimization, treatment adherence, and access to lymphoma oral therapies.
The workshop engaged and informed key stakeholders of these challenges and the day-long discussion helped to shed a light on priority action items for further investigation and investment.
The Foundation published the White Paper, Oral Therapies in Lymphoma: Opportunities and Challenges in Research and Treatment as its latest contribution to the ongoing discussion on the growing importance of the role of oral therapies in the treatment of cancer. The paper outlines the key issues discussed during the workshop, and opportunities and challenges facing patients, the cancer care team, and the research community with respect to the development, accessibility and deliver of oral agents to patients with lymphoma and other blood cancers. Download the White Paper today.
